Current possibilities in therapy for sexually transmitted viral infections


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Objective. To study the efficacy and safety of ingaron (interferon-γ) used in the therapy of sexually transmitted viral infections. Subjects and methods. The study enrolled 45 patients aged 20 to 48 years, among them there were 15 patients diagnosed with anogenital herpetic infections (Subgroups 1A and 1B) and 30 patients diagnosed with anogenital (venereal) warts (Subgroups 2A and 2B). The diagnoses were verified by polymerase chain reaction. Subgroup 1A patients received therapy with ingaron; Subgroup 1B was treated with acyclovir; Subgroup 2A had ingaron in combination with cryodestruction; Subgroup 2B underwent anogenital wart cryodestruction. The patients were followed up for 100-200 days to evaluate the efficiency and safety of therapy. Results. The ingaron- or acyclovir-treated patients were recorded to have no recurrent anogenital herpetic infections in 85.7 and 87.5% of cases, respectively. In the patients with anogenital warts, the efficiency of combined therapy (ingaron + cryodestruction) was significantly higher than that of cryodestruction only (93.3 and 53.3%, respectively). Neither serious adverse reactions nor clinically relevant changes in general and biochemical blood tests during performed therapy were recorded. Conclusion. Ingaron has a high clinical efficacy and safety profile and may be recommended for the therapy of sexually-transmitted viral infections particularly in patients with disease recurrences.

Толық мәтін

Рұқсат жабық

Авторлар туралы

M. Rakhmatulina

State Dermatovenereology and Cosmetology Research Center, Ministry of Health of Russia

Әдебиет тізімі

  1. "World Health Organization (WHO), Department of Reproductive Health and Research. Sexual and reproductive health. Geneva: WHO; 2012 1-36. Available at: http://www.who.int/reproductivehealth/publications/ rtis/9789241503501 (Accessed: March 30, 2014).
  2. Перламутров Ю.Н., Чернова Н.И., Рахматулина M.P., Соколовский Е.В. Федеральные клинические рекомендации по ведению больных генитальным герпесом. М.: Российское общество дерматовенерологов и косметологов; 2013. Available at: http://193.232.7.120/feml/ clinical_ref/0001370965S/HTML/ [Perlamutrov Yu.N., Chernova N.I., Rahmatulina M.R., Sokolovskiy E.V. Federal guidelines for the management of patients with genital herpes. Mrn;oscow: Russian society of dermatologists and cosmetologists; 2013. Available at: http://193.232.7.120/feml/clini-cal_ref/0001370965S/HTML/ (in Russian)]
  3. Перламутров Ю.Н., Рахматулина M.P., Соколовский Е.В., Чернова Н.И. Федеральные клинические рекомендации по ведению больных аногенитальными (венерическими) бородавками. М.: Российское общество дерматовенерологов и косметологов; 2013. Available at: http://193.232.7.120/feml/clinical_ref/0001370952S/HTML/. [Perlamutrov Yu.N., Rahmatulina M.R., Sokolovskiy E.V., Chernova N.I. Federal guidelines for the management of patients with anogenital (venereal) warts. Moscow: Russian society dermatologists and cosmetologists; 2013. Available at: http://193.232.7.120/feml/clinical_ref/0001370952S/HTML/ (in Russian)]
  4. Workowski K.A., Berman S.; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm. Rep. 2010; 59(RR-12): 1-110.
  5. Полетаев А.Б. Клиническая и лабораторная иммунология: избранные лекции. М.: МИА; 2007. 184с. [Poletaev A.B. The clinical and laboratory immunology: Selected lectures. Moscow: MIA; 2007. 184 p. (in Russian)]
  6. Привалова М.а. Изменения местного иммунитета при воспалительных заболеваниях женских половых органов. Вестник новых медицинских технологий. 2008; 15(2): 55-6. [Privalova M.A. Changes in local immunity in inflammatory diseases of the female genital organs. Vestnik novyih meditsinskih tehnologiy. 2008; 15(2): 55-6. (in Russian)]
  7. Bach P.A., Aguet M., Schreiber P.D. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 1997; 15: 563-91.
  8. Cantin E., Tanamachi B., Openshaw H. Gamma interferon (IFN-gamma) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than IFN-gamma ligand null-mutant mice. J. Virol. 1999; 73(6): 5196-200.
  9. Parr М.В., Parr E.L. Interferon-gamma up-regulates intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 and recruits lymphocytes into the vagina of immune mice challenged with herpes simplex virus-2. Immunology. 2000; 99(4): 540-5.
  10. Larsen J., Peters K., Petersen C.S., Damkjaer K., Albrectsen J., Weismann K. Interferon alpha-2b treatment of symptomatic chronic vulvodynia associated with koilocytosis. Acta Derm. Venereol. 1993; 73(5): 385-7.
  11. Keay S., Teng N., M. Eisenberg M. Topical interferon for treating condyloma acuminata in women. J. Infect. Dis. 1988; 158(5): 934-9.
  12. Petersen C.S., Bjerring P., Larsen J., Blaakaer J., Hagdrup H., From E., Obergaard L. Systemic interferon alpha-2b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study. Genitourin. Med. 1991; 67(2): 99-102.
  13. Ноhеnlеиtnеr U., Landthaler M., Braun-Falco O. Postoperative adjuvant therapy with interferon alfa-2B following laser surgery of condylomata acuminate. Hautarzt. 1990; 41(10): 545-8.
  14. Stanley M. A practitioner’s guide to understanding immunity to human papillomavirus. US Obstet. Gynaecol. 2009; 4(1): 10-5.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© ООО «Бионика Медиа», 2015

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>